$4000 | Single User
$8000 | Site License
$12000 | Enterprise License

Bioabsorbable Stents - Medical Devices Pipeline Assessment, 2015
[Lowest Price Guaranteed: $4,000]

Published by Global Data: 01 Dec 2015 | 17098 | In Stock
Related Topics: Medical , Medical Devices , Stent

Introduction

Bioabsorbable Stents - Medical Devices Pipeline Assessment, 2015

Summary

GlobalData's Medical Devices sector report, “Bioabsorbable Stents - Medical Devices Pipeline Assessment, 2015" provides an overview of Bioabsorbable Stents currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Bioabsorbable Stents pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

- Extensive coverage of the Bioabsorbable Stents under development

- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities

- The report reviews the major players involved in the development of Bioabsorbable Stents and list all their pipeline projects

- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage

- The report provides key clinical trial data of ongoing trials specific to pipeline products

- Recent developments in the segment / industry

Reasons to buy

The report enables you to -

- Formulate significant competitor information, analysis, and insights to improve R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of Bioabsorbable Stents under development

- Develop market-entry and market expansion strategies

- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline

- In-depth analysis of the product’s current stage of development, territory and estimated launch date

Table of Contents
for Bioabsorbable Stents - Medical Devices Pipeline Assessment, 2015

  • 1 Table of Contents

    1 Table of Contents 2

    1.1 List of Tables 4

    1.2 List of Figures 8

    2 Introduction 9

    2.1 Bioabsorbable Stents Overview 9

    3 Products under Development 10

    3.1 Bioabsorbable Stents - Pipeline Products by Stage of Development 10

    3.2 Bioabsorbable Stents - Pipeline Products by Territory 11

    3.3 Bioabsorbable Stents - Pipeline Products by Regulatory Path 12

    3.4 Bioabsorbable Stents - Pipeline Products by Estimated Approval Date 13

    3.5 Bioabsorbable Stents - Ongoing Clinical Trials 14

    4 Bioabsorbable Stents - Pipeline Products under Development by Companies 15

    4.1 Bioabsorbable Stents Companies - Pipeline Products by Stage of Development 15

    4.2 Bioabsorbable Stents - Pipeline Products by Stage of Development 17

    5 Bioabsorbable Stents Companies and Product Overview 19

    5.1 Abbott Vascular Inc. Company Overview 19

    5.1.1 Abbott Vascular Inc. Pipeline Products & Ongoing Clinical Trials Overview 19

    5.2 AlviMedica Medical Technologies Inc. Company Overview 34

    5.2.1 AlviMedica Medical Technologies Inc. Pipeline Products & Ongoing Clinical Trials Overview 34

    5.3 Amaranth Medical, Inc. Company Overview 36

    5.3.1 Amaranth Medical, Inc. Pipeline Products & Ongoing Clinical Trials Overview 36

    5.4 Arterius Ltd Company Overview 44

    5.4.1 Arterius Ltd Pipeline Products & Ongoing Clinical Trials Overview 44

    5.5 Biosensors International Group, Ltd. Company Overview 45

    5.5.1 Biosensors International Group, Ltd. Pipeline Products & Ongoing Clinical Trials Overview 45

    5.6 Biotronik SE & Co. KG Company Overview 49

    5.6.1 Biotronik SE & Co. KG Pipeline Products & Ongoing Clinical Trials Overview 49

    5.7 Boston Scientific Corporation Company Overview 54

    5.7.1 Boston Scientific Corporation Pipeline Products & Ongoing Clinical Trials Overview 54

    5.8 Cardionovum GmbH Company Overview 59

    5.8.1 Cardionovum GmbH Pipeline Products & Ongoing Clinical Trials Overview 59

    5.9 Elixir Medical Corporation Company Overview 63

    5.9.1 Elixir Medical Corporation Pipeline Products & Ongoing Clinical Trials Overview 63

    5.10 HangZhou HuaAn Biotechnology Co., Ltd. Company Overview 69

    5.10.1 HangZhou HuaAn Biotechnology Co., Ltd. Pipeline Products & Ongoing Clinical Trials Overview 69

    5.11 Icon Interventional Systems, Inc. Company Overview 70

    5.11.1 Icon Interventional Systems, Inc. Pipeline Products & Ongoing Clinical Trials Overview 70

    5.12 Japan Stent Technology Co., Ltd. Company Overview 71

    5.12.1 Japan Stent Technology Co., Ltd. Pipeline Products & Ongoing Clinical Trials Overview 71

    5.13 Lepu Medical Technology (Beijing) Co., Ltd. Company Overview 72

    5.13.1 Lepu Medical Technology (Beijing) Co., Ltd. Pipeline Products & Ongoing Clinical Trials Overview 72

    5.14 Medlogics Device Corporation Company Overview 76

    5.14.1 Medlogics Device Corporation Pipeline Products & Ongoing Clinical Trials Overview 76

    5.15 Meril Life Sciences Pvt. Ltd. Company Overview 77

    5.15.1 Meril Life Sciences Pvt. Ltd. Pipeline Products & Ongoing Clinical Trials Overview 77

    5.16 MicroPort Scientific Corporation Company Overview 80

    5.16.1 MicroPort Scientific Corporation Pipeline Products & Ongoing Clinical Trials Overview 80

    5.17 NanoCoeur, Inc. Company Overview 82

    5.17.1 NanoCoeur, Inc. Pipeline Products & Ongoing Clinical Trials Overview 82

    5.18 Northwestern University Company Overview 83

    5.18.1 Northwestern University Pipeline Products & Ongoing Clinical Trials Overview 83

    5.19 OrbusNeich Company Overview 85

    5.19.1 OrbusNeich Pipeline Products & Ongoing Clinical Trials Overview 85

    5.20 REVA Medical, Inc. Company Overview 87

    5.20.1 REVA Medical, Inc. Pipeline Products & Ongoing Clinical Trials Overview 87

    5.21 S3V Vascular Technologies Company Overview 93

    5.21.1 S3V Vascular Technologies Pipeline Products & Ongoing Clinical Trials Overview 93

    5.22 Shanghai MicroPort Medical (Group) Co., Ltd. Company Overview 94

    5.22.1 Shanghai MicroPort Medical (Group) Co., Ltd. Pipeline Products & Ongoing Clinical Trials Overview 94

    5.23 Tepha, Inc. Company Overview 96

    5.23.1 Tepha, Inc. Pipeline Products & Ongoing Clinical Trials Overview 96

    5.24 Terumo Corporation Company Overview 98

    5.24.1 Terumo Corporation Pipeline Products & Ongoing Clinical Trials Overview 98

    5.25 Xenogenics Corporation Company Overview 100

    5.25.1 Xenogenics Corporation Pipeline Products & Ongoing Clinical Trials Overview 100

    5.26 Zorion Medical Company Overview 104

    5.26.1 Zorion Medical Pipeline Products & Ongoing Clinical Trials Overview 104

    6 Bioabsorbable Stents- Recent Developments 106

    7 Appendix 121

    7.1 Methodology 121

    7.2 About GlobalData 123

    7.3 Contact Us 124

    7.4 Disclaimer 124

List Of Tables
in Bioabsorbable Stents - Medical Devices Pipeline Assessment, 2015

1.1 List of Tables

Table 1: Bioabsorbable Stents - Pipeline Products by Stage of Development 10

Table 2: Bioabsorbable Stents - Pipeline Products by Territory 11

Table 3: Bioabsorbable Stents - Pipeline Products by Regulatory Path 12

Table 4: Bioabsorbable Stents - Pipeline Products by Estimated Approval Date 13

Table 5: Bioabsorbable Stents - Ongoing Clinical Trials 14

Table 6: Bioabsorbable Stents Companies - Pipeline Products by Stage of Development 15

Table 7: Bioabsorbable Stents - Pipeline Products by Stage of Development 17

Table 8: Abbott Vascular Inc. Pipeline Products & Ongoing Clinical Trials Overview 19

Table 9: Absorb Bioresorbable Vascular Scaffold - Product Status 20

Table 10: Absorb Bioresorbable Vascular Scaffold - Product Description 20

Table 11: Second Generation Bioresorbable Vascular Scaffold - Product Status 21

Table 12: Second Generation Bioresorbable Vascular Scaffold - Product Description 21

Table 13: Abbott Vascular Inc. - Ongoing Clinical Trials Overview 22

Table 14: Absorb Bioresorbable Vascular Scaffold - A Clinical Evaluation of Absorb BVS, the Bioresorbable Vascular Scaffold, in the Treatment of Subjects with de Novo Native Coronary Artery Lesions in Chinese Population 25

Table 15: Absorb Bioresorbable Vascular Scaffold - A Clinical Evaluation of Absorb BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold In The Treatment Of Subjects with De Novo Native Coronary Artery Lesions 25

Table 16: Absorb Bioresorbable Vascular Scaffold - A Clinical Evaluation of Absorb BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects with de Novo Native Coronary Artery Lesions 25

Table 17: Absorb Bioresorbable Vascular Scaffold - A Clinical Evaluation to Compare the Safety, Efficacy and Performance of ABSORB Everolimus Eluting Bioresorbable Vascular Scaffold System Against XIENCE Everolimus Eluting Coronary Stent System in the Treatment of Subjects with Ischemic Heart Disease Caused by de Novo Native Coronary Artery Lesions: ABSORB II Randomized Controlled Trial 26

Table 18: Absorb Bioresorbable Vascular Scaffold - A Continuation in the Clinical Evaluation of the Abbott Vascular Everolimus-Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects with de Novo Native Coronary Artery Lesions: ABSORB EXTEND Clinical Investigation 26

Table 19: Absorb Bioresorbable Vascular Scaffold - A Multicenter Prospective Natural History Study Using Multimodality Imaging in Patients with Acute Coronary Syndromes - PROSPECT II (Natural History Study), Combined with a Randomized, Controlled, Intervention Study - PROSPECT ABSORB (Randomized Trial) 27

Table 20: Absorb Bioresorbable Vascular Scaffold - A Post-market Registry of Patients with de Novo Lesions in Previously Untreated Vessels Treated with Absorb BVS 27

Table 21: Absorb Bioresorbable Vascular Scaffold - A Prospective, Randomized Trial of SYNERGY Bioresorbable Polymer Coated Stents Versus Absorb Bioresorbable Backbone Stents in Patients Undergoing Coronary Stenting (ISAR-RESORB) 28

Table 22: Absorb Bioresorbable Vascular Scaffold - A Randomized Controlled Comparison of Optical Coherence Tomography Guidance and Angiography-only Guidance for Percutaneous Coronary Intervention with Bioresorbable Vascular Scaffold 28

Table 23: Absorb Bioresorbable Vascular Scaffold - ABSORB Bioresorbable Scaffold versus Xience Metallic Stent for Prevention of Restenosis Following Percutaneous Coronary Intervention in Patients at High Risk of Restenosis 28

Table 24: Absorb Bioresorbable Vascular Scaffold - Absorb Bioresorbable Scaffold Vs. Drug Coated Balloon for Treatment of In-stent-restenosis 29

Table 25: Absorb Bioresorbable Vascular Scaffold - Amsterdam Investigator-initiated Absorb Strategy All-comers Trial (AIDA Trial): A Clinical Evaluation Comparing the Efficacy and Performance of ABSORB Everolimus Eluting Bioresorbable Vascular Scaffold Strategy Versus the XIENCE Family (XIENCE PRIME or XIENCE Xpedition) Everolimus Eluting Coronary Stent Strategy in the Treatment of Coronary Lesions in Consecutive All-comers 29

Table 26: Absorb Bioresorbable Vascular Scaffold - An International Post-market Registry of Patients With de Novo Lesions in Previously Untreated Vessels Treated With Absorb Bioresorbable Vascular Scaffold (Absorb BVS): ABSORB FIRST Registry 30

Table 27: Absorb Bioresorbable Vascular Scaffold - Comparison of the ABSORB Everolimus Eluting Bioresorbable Vascular Scaffold System With a Drug- Eluting Metal Stent (Xience) in Acute ST-Elevation Myocardial Infarction 30

Table 28: Absorb Bioresorbable Vascular Scaffold - Comprehensive Imaging and Interventional Therapy Studies for Arteriogenic Erectile Dysfunction and Lower Urinary Tract Symptoms: a Multi-modality, Multi-specialty Collaborative Study (PERFECT Program) 30

Table 29: Absorb Bioresorbable Vascular Scaffold - Everolimus-eluting Bioresorbable Vascular Scaffold System in the Treatment of Cardiac Allograft Vasculopathy in Heart Transplant Recipients: A Prospective Multicenter Pilot Study 31

Table 30: Absorb Bioresorbable Vascular Scaffold - German-Austrian Register to Evaluate the Short and Long-term Safety and Therapy Outcomes of the ABSORB Everolimus-Eluting Bioresorbable Vascular Scaffold System in Patients With Coronary Artery Stenosis 31

Table 31: Absorb Bioresorbable Vascular Scaffold - Impact of Vascular Reparative Therapy on Vasomotor Function and Myocardial Perfusion: A Randomized H215O PET/CT Study 32

Table 32: Absorb Bioresorbable Vascular Scaffold - Optimal Lesion Preparation with Non-compliant Balloons for the Implantation of Bioresorbable Vascular Scaffolds (BVS) - OPRENBIS Study 32

Table 33: Absorb Bioresorbable Vascular Scaffold - Performance of Bioresorbable Scaffold in Primary Percutaneous Intervention of ST Elevation Myocardial Infarct (BVS in STEMI) 32

Table 34: Absorb Bioresorbable Vascular Scaffold - Safety and Feasibility of Bioabsorbable Everolimus-Eluting Stents for Patients with Internal Pudendal Artery-related Arteriogenic Erectile Dysfunction (PERFECT-ABSORB) 33

Table 35: AlviMedica Medical Technologies Inc. Pipeline Products & Ongoing Clinical Trials Overview 34

Table 36: Coracto Rapamycin-Eluting Coronary Stent - Product Status 35

Table 37: Coracto Rapamycin-Eluting Coronary Stent - Product Description 35

Table 38: Amaranth Medical, Inc. Pipeline Products & Ongoing Clinical Trials Overview 36

Table 39: APTITUDE Bioresorbable Drug-Eluting Coronary Scaffold - Product Status 37

Table 40: APTITUDE Bioresorbable Drug-Eluting Coronary Scaffold - Product Description 37

Table 41: FORTITUDE Scaffold - Product Status 38

Table 42: FORTITUDE Scaffold - Product Description 38

Table 43: Next Generation FORTITUDE Scaffold - Product Status 39

Table 44: Next Generation FORTITUDE Scaffold - Product Description 39

Table 45: Amaranth Medical, Inc. - Ongoing Clinical Trials Overview 40

Table 46: FORTITUDE Scaffold - Restoring Endoluminal Narrowing Using Bioresorbable Scaffolds - European Trial 41

Table 47: Next Generation FORTITUDE Scaffold - Amaranth Endovascular Study of a Drug-eluting Bioresorbable Coronary Scaffold 42

Table 48: APTITUDE Bioresorbable Drug-Eluting Coronary Scaffold - Restoring Endoluminal Narrowing Using Bioresorbable Scaffolds - Extended Trial II 43

Table 49: Arterius Ltd Pipeline Products & Ongoing Clinical Trials Overview 44

Table 50: Arteriosorb Absorbable Drug-Eluting Scaffold - Product Status 44

Table 51: Arteriosorb Absorbable Drug-Eluting Scaffold - Product Description 44

Table 52: Biosensors International Group, Ltd. Pipeline Products & Ongoing Clinical Trials Overview 45

Table 53: Sparrow Drug Eluting Stent System - Product Status 46

Table 54: Sparrow Drug Eluting Stent System - Product Description 46

Table 55: Biosensors International Group, Ltd. - Ongoing Clinical Trials Overview 47

Table 56: Sparrow Drug Eluting Stent System - CARE II Clinical Trial 48

Table 57: Biotronik SE & Co. KG Pipeline Products & Ongoing Clinical Trials Overview 49

Table 58: DREAMS - Product Status 50

Table 59: DREAMS - Product Description 50

Table 60: DREAMS 2 - Product Status 51

Table 61: DREAMS 2 - Product Description 51

Table 62: Biotronik SE & Co. KG - Ongoing Clinical Trials Overview 52

Table 63: DREAMS 2 - BIOTRONIK - Safety and Clinical Performance of the Drug Eluting Absorbable Metal Scaffold (DREAMS 2nd Generation) in the Treatment of Subjects with de Novo Lesions in Native Coronary Arteries: BIOSOLVE-II 53

Table 64: Boston Scientific Corporation Pipeline Products & Ongoing Clinical Trials Overview 54

Table 65: Fully Resorbable Drug-Eluting Scaffold System - Product Status 55

Table 66: Fully Resorbable Drug-Eluting Scaffold System - Product Description 55

Table 67: Next Generation SYNERGY - Product Status 56

Table 68: Next Generation SYNERGY - Product Description 56

Table 69: Boston Scientific Corporation - Ongoing Clinical Trials Overview 57

Table 70: Fully Resorbable Drug-Eluting Scaffold System - Fully Absorbable Scaffold Feasibility Study (FAST) 58

Table 71: Cardionovum GmbH Pipeline Products & Ongoing Clinical Trials Overview 59

Table 72: ReNATURAL (M) - Product Status 60

Table 73: ReNATURAL (M) - Product Description 60

Table 74: ReNATURAL (P) - Product Status 61

Table 75: ReNATURAL (P) - Product Description 61

Table 76: RESORB - Product Status 62

Table 77: RESORB - Product Description 62

Table 78: Elixir Medical Corporation Pipeline Products & Ongoing Clinical Trials Overview 63

Table 79: DESolve 100 Novolimus Eluting Bioresorbable Coronary Scaffold System - Product Status 64

Table 80: DESolve 100 Novolimus Eluting Bioresorbable Coronary Scaffold System - Product Description 64

Table 81: DESolve Myolimus Eluting Bioresorbable Coronary Scaffold System - Product Status 65

Table 82: DESolve Myolimus Eluting Bioresorbable Coronary Scaffold System - Product Description 65

Table 83: DESolve Novolimus Eluting Bioresorbable Coronary Scaffold System - Product Status 66

Table 84: DESolve Novolimus Eluting Bioresorbable Coronary Scaffold System - Product Description 66

Table 85: Elixir Medical Corporation - Ongoing Clinical Trials Overview 67

Table 86: DESolve Novolimus Eluting Bioresorbable Coronary Scaffold System - Post-market Evaluation of Desolve Novolimus Eluting Bioresorbable Coronary Scaffold System in the Treatment of Patients with De Novo Native Coronary Artery Lesions 68

Table 87: DESolve Novolimus Eluting Bioresorbable Coronary Scaffold System - X-Pand is Intended to Use the DESolve Scaffold System in Treatment of CAD Patients, by Including "Real World" Use of the DESolve Scaffold Over a Broad Spectrum of Geographies, A Wide Variety of Practicing Clinicians & A Minimum Degree of Selection Criteria 68

Table 88: HangZhou HuaAn Biotechnology Co., Ltd. Pipeline Products & Ongoing Clinical Trials Overview 69

Table 89: Xinsorb BRS - Product Status 69

Table 90: Xinsorb BRS - Product Description 69

Table 91: Icon Interventional Systems, Inc. Pipeline Products & Ongoing Clinical Trials Overview 70

Table 92: Dissolving Stent - Product Status 70

Table 93: Dissolving Stent - Product Description 70

Table 94: Japan Stent Technology Co., Ltd. Pipeline Products & Ongoing Clinical Trials Overview 71

Table 95: Bioabsorbable Stent - Product Status 71

Table 96: Bioabsorbable Stent - Product Description 71

Table 97: Lepu Medical Technology (Beijing) Co., Ltd. Pipeline Products & Ongoing Clinical Trials Overview 72

Table 98: NeoVas Bioresorbable Coronary Scaffold (BCS) - Product Status 73

Table 99: NeoVas Bioresorbable Coronary Scaffold (BCS) - Product Description 73

Table 100: Lepu Medical Technology (Beijing) Co., Ltd. - Ongoing Clinical Trials Overview 74

Table 101: NeoVas Bioresorbable Coronary Scaffold (BCS) - Clinical Evaluation of a Bioresorbable Sirolimus-eluting Coronary Scaffold in the Treatment of Patients With de Novo Coronary Artery Lesion (NeoVas): a Single Arm Registry Study 75

Table 102: NeoVas Bioresorbable Coronary Scaffold (BCS) - Clinical Evaluation of a Bioresorbable Sirolimus-eluting Coronary Scaffold in the Treatment of Patients with Denovo Coronary Artery Lesion (NeoVas): Randomized Controlled Trial 75

Table 103: Medlogics Device Corporation Pipeline Products & Ongoing Clinical Trials Overview 76

Table 104: COBRA-P Drug Eluting Stent - Product Status 76

Table 105: COBRA-P Drug Eluting Stent - Product Description 76

Table 106: Meril Life Sciences Pvt. Ltd. Pipeline Products & Ongoing Clinical Trials Overview 77

Table 107: BIOMIME AURA - Product Status 78

Table 108: BIOMIME AURA - Product Description 78

Table 109: MeRes - Product Status 79

Table 110: MeRes - Product Description 79

Table 111: MicroPort Scientific Corporation Pipeline Products & Ongoing Clinical Trials Overview 80

Table 112: Firefalcon Bioresorbable Device - Product Status 81

Table 113: Firefalcon Bioresorbable Device - Product Description 81

Table 114: NanoCoeur, Inc. Pipeline Products & Ongoing Clinical Trials Overview 82

Table 115: Nanocoating Cardiac Stent - Product Status 82

Table 116: Nanocoating Cardiac Stent - Product Description 82

Table 117: Northwestern University Pipeline Products & Ongoing Clinical Trials Overview 83

Table 118: Liquid Biodegradable Drug Eluting Stent - Product Status 84

Table 119: Liquid Biodegradable Drug Eluting Stent - Product Description 84

Table 120: OrbusNeich Pipeline Products & Ongoing Clinical Trials Overview 85

Table 121: Acute BRS - Product Status 85

Table 122: Acute BRS - Product Description 85

Table 123: Cura Stent - Product Status 86

Table 124: Cura Stent - Product Description 86

Table 125: REVA Medical, Inc. Pipeline Products & Ongoing Clinical Trials Overview 87

Table 126: Fantom Sirolimus-Eluting Bioresorbable Scaffold - Product Status 88

Table 127: Fantom Sirolimus-Eluting Bioresorbable Scaffold - Product Description 88

Table 128: ReZolve Sirolimus-Eluting Bioresorbable Coronary Scaffold - Product Status 89

Table 129: ReZolve Sirolimus-Eluting Bioresorbable Coronary Scaffold - Product Description 89

Table 130: ReZolve2 - Product Status 90

Table 131: ReZolve2 - Product Description 90

Table 132: REVA Medical, Inc. - Ongoing Clinical Trials Overview 91

Table 133: Fantom Sirolimus-Eluting Bioresorbable Scaffold - FANTOM I Clinical Trial 92

Table 134: Fantom Sirolimus-Eluting Bioresorbable Scaffold - Pilot Study of the REVA Sirolimus-Eluting Bioresorbable Coronary Scaffold 92

Table 135: Fantom Sirolimus-Eluting Bioresorbable Scaffold - Safety & Performance Study of the FANTOM Sirolimus-Eluting Bioresorbable Coronary Scaffold (FANTOM II) 92

Table 136: S3V Vascular Technologies Pipeline Products & Ongoing Clinical Trials Overview 93

Table 137: 3V Avatar - Product Status 93

Table 138: 3V Avatar - Product Description 93

Table 139: Shanghai MicroPort Medical (Group) Co., Ltd. Pipeline Products & Ongoing Clinical Trials Overview 94

Table 140: Bioresorbable Scaffold System - Product Status 95

Table 141: Bioresorbable Scaffold System - Product Description 95

Table 142: Tepha, Inc. Pipeline Products & Ongoing Clinical Trials Overview 96

Table 143: TephaFLEX Absorbable Stent - Product Status 97

Table 144: TephaFLEX Absorbable Stent - Product Description 97

Table 145: Terumo Corporation Pipeline Products & Ongoing Clinical Trials Overview 98

Table 146: Bioresorbable Coronary Stent - Product Status 99

Table 147: Bioresorbable Coronary Stent - Product Description 99

Table 148: Xenogenics Corporation Pipeline Products & Ongoing Clinical Trials Overview 100

Table 149: Ideal BioStent - First Generation - Product Status 101

Table 150: Ideal BioStent - First Generation - Product Description 101

Table 151: Ideal BioStent - Second Generation - Product Status 102

Table 152: Ideal BioStent - Second Generation - Product Description 102

Table 153: Whisper Coronary Stent System - Product Status 103

Table 154: Whisper Coronary Stent System - Product Description 103

Table 155: Zorion Medical Pipeline Products & Ongoing Clinical Trials Overview 104

Table 156: ZMED Absorbable Drug Eluting Stent - Product Status 105

Table 157: ZMED Absorbable Drug Eluting Stent - Product Description 105

Table 158: Glossary 122

List Of Figures, Charts and Diagrams
in Bioabsorbable Stents - Medical Devices Pipeline Assessment, 2015

1.2 List of Figures

Figure 1: Bioabsorbable Stents - Pipeline Products by Stage of Development 10

Figure 2: Bioabsorbable Stents - Pipeline Products by Territory 11

Figure 3: Bioabsorbable Stents - Pipeline Products by Regulatory Path 12

Figure 4: Bioabsorbable Stents - Pipeline Products by Estimated Approval Date 13

Figure 5: Bioabsorbable Stents - Ongoing Clinical Trials 14

Additional Details

Publisher

Global Data

Publisher Information

Reference

17098 | GDME0100EPD

Number of Pages

124

Report Format

PDF

Global Data Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Global Bioabsorbable Stents Market Research Report Forecast 2017-2022
Delivery of the Report will take 48-72 hours once order is placed.The Global Bioabsorbable Stents M...
05 Jul 2017 by S&P Consulting USD $2,800 More Info
Coronary Stents Market by Product (Drug-eluting Stent, Bare-metal Stent, and Bioabsorbable Vascular Stent), Biomaterials {Metallic (Cobalt Chromium, Platinum Chromium, Nickel Chromium, and Stainless Steel), Polymeric, and Natural Biomaterials), End User (Hospital & Clinic and Ambulatory Surgical Centers) - Global Opportunity Analysis and Industry Forecast, 2014-2022
Coronary stents are small expandable tubes that are used to treat narrowed or blocked coronary arter...
04 Apr 2017 by Allied Market Research USD $5,370 More Info
Bioabsorbable Stents (BAS) - Medical Devices Pipeline Assessment, 2016
Bioabsorbable Stents (BAS) - Medical Devices Pipeline Assessment, 2016SummaryGlobalData's Medical De...
01 Nov 2016 by Global Data USD $4,000 More Info
Bioabsorbable Stents Market by Material (Polymer, Metal), Procedure (Invasive), Absorption Rate (Slow, Fast), Drugs (Limus drugs, Paclitaxel), Application (CAD, PAD), End User (Hospital, Cardiac Centers) - Global Forecast to 2021
The global bioabsorbable stents market is expected to reach USD 2.4 billion by 2021 from USD 0.4 bil...
16 Jun 2016 by MarketsandMarkets USD $5,650 More Info
Bioabsorbable Stents Market: By Material (Polymeric, Metallic); By Application (Coronary Artery Disease, Peripheral Artery Disease); By End- User (General Hospitals, Cardiac Centers, Surgical Centers) & By Geography-Forecast (2016-2021)
Stents are commonly used in the treatment of blocked arteries. Bioabsorbable stents are defined as f...
23 Feb 2016 by USD $5,250 More Info
Bioabsorbable Scaffolds - US Analysis and Market Forecasts
Bioabsorbable Scaffolds - US Analysis and Market ForecastsSummaryCoronary artery disease (CAD) and p...
01 Aug 2015 by Global Data USD $4,450 More Info
Bioabsorbable Scaffolds - 5EU Analysis and Market Forecasts
Bioabsorbable Scaffolds - 5EU Analysis and Market ForecastsSummaryCoronary artery disease (CAD) and ...
01 Aug 2015 by Global Data USD $4,450 More Info
Bioabsorbable Scaffolds - APAC Analysis and Market Forecasts
Bioabsorbable Scaffolds - APAC Analysis and Market ForecastsSummaryCoronary artery disease (CAD) and...
01 Aug 2015 by Global Data USD $4,450 More Info
Bioabsorbable Scaffolds - South America Analysis and Market Forecasts
Bioabsorbable Scaffolds - South America Analysis and Market ForecastsSummaryCoronary artery disease ...
01 Aug 2015 by Global Data USD $4,450 More Info
Bioabsorbable Scaffolds - Current and Future Players
Bioabsorbable Scaffolds - Current and Future PlayersSummaryCoronary artery disease (CAD) and periphe...
01 Aug 2015 by Global Data USD $3,500 More Info

This report is published by Global Data

Download Free Report Summary PDF

Bioabsorbable Stents - Medical Devices Pipeline Assessment, 2015 | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...